Sign up to save your podcasts
Or
Share NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
View all episodes
By NEJM Group
4.4
120120 ratings
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
129 Listeners
Medicine and Science from The BMJ
37 Listeners
NEJM Journal Watch Podcasts: Clinical Conversations
55 Listeners
NEJM This Week
318 Listeners
JACC Podcast
162 Listeners
JAMA Clinical Reviews
484 Listeners
Mayo Clinic Talks
276 Listeners
JAMA Medical News
87 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Leadership Conversations
7 Listeners
Core IM | Internal Medicine Podcast
1,092 Listeners
Curbside Consults
90 Listeners
Annals On Call Podcast
179 Listeners
The Clinical Problem Solvers
508 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
The Curious Clinicians
361 Listeners
Infectious Disease Puscast
78 Listeners
NEJM AI Grand Rounds
50 Listeners
Intention to Treat
30 Listeners
Not Otherwise Specified
45 Listeners